- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Trash Feet and Mobile Thrombus/Atheroma
Four months after coronary artery bypass surgery, a 77-year-old man began to suffer severe pain in his feet. Multiple necrotic areas developed on the toes.
Four months after coronary artery bypass surgery, a 77-year-old man began to suffer severe pain in his feet. Multiple necrotic areas developed on the toes (A and B).
Drs Emanual Goldberg and Osama Samuel of Beth Israel Medical Center in New York City made the diagnosis of "trash feet." This complication can occur following cardiovascular surgery (usually abdominal aortic aneurysm resection) when embolization of intra-arterial material, which often contains cholesterol, causes ischemia.
This patient's dorsalis pedes and posterior tibial pulses remained palpable. There was some mild associated renal failure. No eosinophilia was noted.
Transesophageal echocardiography showed a large, mobile thrombus/atheroma in the descending thoracic aorta (C).
Treatment included heparin, aspirin, prostaglandin E1, and long-term warfarin therapy. The mobile thrombus/atheroma disappeared without obvious further embolization.
Amputation may be required if the pain becomes intolerable. In this patient, the necrotic portions of the toes sloughed off, and the pain largely subsided.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
